ZA911720B - Sustained release pharmaceutical composition - Google Patents

Sustained release pharmaceutical composition

Info

Publication number
ZA911720B
ZA911720B ZA911720A ZA911720A ZA911720B ZA 911720 B ZA911720 B ZA 911720B ZA 911720 A ZA911720 A ZA 911720A ZA 911720 A ZA911720 A ZA 911720A ZA 911720 B ZA911720 B ZA 911720B
Authority
ZA
South Africa
Prior art keywords
sustained release
pharmaceutical composition
release pharmaceutical
drug
composition
Prior art date
Application number
ZA911720A
Other languages
English (en)
Inventor
Timothy James Grattan
James Grattan Timothy
Original Assignee
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group Plc filed Critical Beecham Group Plc
Publication of ZA911720B publication Critical patent/ZA911720B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585Ion exchange resins, e.g. polystyrene sulfonic acid resin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Confectionery (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA911720A 1990-03-12 1991-03-08 Sustained release pharmaceutical composition ZA911720B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909005498A GB9005498D0 (en) 1990-03-12 1990-03-12 Composition

Publications (1)

Publication Number Publication Date
ZA911720B true ZA911720B (en) 1992-02-26

Family

ID=10672453

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA911720A ZA911720B (en) 1990-03-12 1991-03-08 Sustained release pharmaceutical composition

Country Status (14)

Country Link
EP (1) EP0519950B1 (de)
JP (1) JPH05504574A (de)
AT (1) ATE117893T1 (de)
AU (1) AU643263B2 (de)
CA (1) CA2077994A1 (de)
DE (1) DE69107202T2 (de)
DK (1) DK0519950T3 (de)
ES (1) ES2069880T3 (de)
GB (1) GB9005498D0 (de)
GR (1) GR3015821T3 (de)
HK (1) HK1004529A1 (de)
IE (1) IE65123B1 (de)
WO (1) WO1991013612A1 (de)
ZA (1) ZA911720B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
CA2269679A1 (en) * 1996-12-20 1998-07-02 Warner-Lambert Company Antitussive drugs delivered by partially coated ion exchange resins
EP1117384A1 (de) 1998-10-01 2001-07-25 Elan Pharma International Limited Nanopartikelformulierungen mit kontrollierter wirkstofffreisetzung
DE60232290D1 (de) * 2001-04-09 2009-06-25 Rohm & Haas Kontrollierte Auflösung von Wirkstoffen
US9149440B2 (en) 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
US20050238695A1 (en) * 2004-04-27 2005-10-27 Atma Chaudhari Lozenge for delivery of dextromethorphan
US8313770B2 (en) * 2007-05-30 2012-11-20 Neos Therapeutics, Lp Modifying drug release in suspensions of ionic resin systems
US20130190299A1 (en) 2010-06-30 2013-07-25 Victoria Link Ltd. Methods and compositions for treatment of multiple sclerosis
WO2017017699A1 (en) * 2015-07-27 2017-02-02 Sun Pharma Advanced Research Company Limited Drug loaded nanoresin particles
EP4041309A4 (de) * 2019-10-10 2023-11-01 Brillian Pharma Inc. Pharmazeutische zusammensetzung auf der basis von mikronisiertem wirkstoffresinat und verfahren zu ihrer herstellung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990332A (en) * 1958-04-02 1961-06-27 Wallace & Tiernan Inc Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith
US4221778A (en) * 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
US4788055A (en) * 1985-12-09 1988-11-29 Ciba-Geigy Corporation Resinate sustained release dextromethorphan composition
US4894239A (en) * 1987-06-02 1990-01-16 Takeda Chemical Industries, Ltd. Sustained-release preparation and production thereof
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes

Also Published As

Publication number Publication date
ES2069880T3 (es) 1995-05-16
DE69107202T2 (de) 1995-05-24
AU643263B2 (en) 1993-11-11
HK1004529A1 (en) 1998-11-27
GR3015821T3 (en) 1995-07-31
DK0519950T3 (da) 1995-04-10
CA2077994A1 (en) 1991-09-13
GB9005498D0 (en) 1990-05-09
JPH05504574A (ja) 1993-07-15
DE69107202D1 (de) 1995-03-16
IE910797A1 (en) 1991-09-25
IE65123B1 (en) 1995-10-04
EP0519950A1 (de) 1992-12-30
ATE117893T1 (de) 1995-02-15
WO1991013612A1 (en) 1991-09-19
EP0519950B1 (de) 1995-02-01
AU7348391A (en) 1991-10-10

Similar Documents

Publication Publication Date Title
GR3005477T3 (de)
HU9601008D0 (en) Sustained release formulations for 24 hour release of metoprolol
AU4355693A (en) Ultrafine powder for inhalation and production thereof
HUT76807A (en) Inhalation composition
EP0951917A3 (de) Teilchenverabreichung, insbesondere von therapeutischen Mitteln im pulverisierten Zustand
ZA911720B (en) Sustained release pharmaceutical composition
MY106371A (en) Oral pharmaceutical compositions in unit dosage form
AU566228B2 (en) Compressed hydroxybutryic acid polymer retarded release vehicle
MX9803918A (es) Tabletas de liberacion rapida comprendiendo acido tolfenamico o una sal farmaceuticamente aceptable del mismo como ingrediente activo y un metodo para la preparacion de dicha tableta.
MX9600022A (es) Excipiente de liberacion sostenida.
GR3031360T3 (en) Composition based on ibuprofen, for oral usage
CA2176461A1 (en) Method for preparing low dose pharmaceutical products
IT1252181B (it) Composizioni farmaceutiche per la somministrazione nasale di polipeptidi.